A single-arm, open-label study to evaluate the safety and tolerability of infusing HSC835 in patients with hematological malignancies undergoing UCB transplantation using a non-myeloablative conditioning regimen
|Effective start/end date||7/21/13 → 1/31/17|
- NOVARTIS PHARMACEUTICALS CORPORATION
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.